OPKO Health reports developments across a multinational biopharmaceutical and diagnostics business. Recurring updates cover operating results, financial guidance, BioReference laboratory testing services and digital access through BioReference Direct, and RAYALDEE commercialization through EirGen Pharma in Greater China.
The company also reports research collaborations and clinical development from ModeX Therapeutics, including its MSTAR multispecific antibody platform, MDX2301 for COVID-19 prevention, and MDX2003, a tetraspecific T-cell engager for B-cell lymphomas. News also includes pharmaceutical partnerships, diagnostic-service changes, investor presentations, and business updates tied to OPKO's pharmaceutical and diagnostics segments.
OPKO Health, Inc. (NASDAQ: OPK) will report its Q2 2021 operating and financial results on July 29, 2021, after U.S. market close. The company will provide a detailed business update during a conference call at 4:30 PM ET on the same day. Interested parties can pre-register for the call or access it via the provided webcast link. OPKO focuses on biopharmaceuticals and diagnostics, aiming to lead in rapidly growing markets through innovative technologies. Additional details and a replay will be available on OPKO's website.
OPKO Health, Inc. (NASDAQ: OPK) has entered into a worldwide agreement with CAMP4 Therapeutics for developing therapeutics based on the AntagoNAT technology. This agreement marks a significant step in advancing OPKO's lead compound for Dravet syndrome into clinical trials. OPKO will receive an upfront payment and is eligible for up to $93.5 million in milestone payments, plus royalties on product sales. The collaboration not only enhances OPKO’s focus on drug development but also validates its proprietary technology.
OPKO Health, Inc. (NASDAQ: OPK) will participate in the virtual Ladenburg Thalmann Healthcare Conference on July 13-14, 2021. Management will engage in a fireside chat on July 13 at 8:30 a.m. Eastern Time and will conduct one-on-one virtual meetings with investors throughout the day. The fireside chat will be archived in OPKO Health's Investors section on their website for future viewing. OPKO is focused on establishing a strong market position in biopharmaceuticals and diagnostics, leveraging its innovative technologies.
OPKO Health, Inc. (NASDAQ: OPK) has appointed Katherine Stueland as President and CEO of its subsidiary, GeneDx, Inc. Stueland, previously a Chief Commercial Officer at Invitae Corporation, brings two decades of leadership in the healthcare industry. Under her guidance, GeneDx aims to leverage genomic information to enhance patient care, emphasizing access to diagnostics for rare genetic disorders. The company has been a leading player in genomics for over 20 years, offering a wide array of genetic testing services.
BioReference Laboratories, a subsidiary of OPKO Health (NASDAQ: OPK), has launched a COVID-19 testing program aimed at U.S. crew and guests cruising with Royal Caribbean Group. This program mandates rapid PCR testing for unvaccinated guests prior to embarkation and at the end of their voyage, with additional testing during the cruise as needed. The initiative is designed to enhance safety for travelers, providing results within 40 minutes of arrival at the port. BioReference, a leading lab in the U.S., serves approximately 19 million patients annually and offers extensive testing solutions.
OPKO Health, Inc. (NASDAQ: OPK) has announced a partnership between its subsidiary EirGen Pharma and Nicoya Macau Limited for the commercialization of RAYALDEE in Greater China. The agreement includes an upfront payment of $5 million and additional payments contingent on development milestones, totaling up to $115 million. Nicoya will handle regulatory approvals and commercialization. With an estimated 19 million patients with stage 3 or 4 chronic kidney disease in the region, this collaboration aims to tap into a significant market opportunity.
OPKO Health, Inc. (NASDAQ: OPK) announced that its subsidiary, EirGen Pharma, has agreed to sell its Waterford, Ireland facility to Horizon Therapeutics for $65 million. This sale will streamline EirGen’s operations, focusing on oral solid dose products. CEO Phillip Frost emphasized the transaction strengthens OPKO's balance sheet while cutting expenses and enhancing efficiency. The deal is expected to close in about a month, pending governmental approvals.
OPKO Health (NASDAQ: OPK) will participate in the Jefferies Virtual Healthcare Conference from June 1-4, 2021. Management will engage in a fireside chat on June 2 at 11:30 a.m. Eastern time. The chat will be available via live webcast and archived on OPKO Health’s investor website. Additionally, one-on-one virtual meetings with investors will occur throughout the day. OPKO Health focuses on biopharmaceuticals and diagnostics, aiming to lead in growing markets through innovative technologies.
OPKO Health (NASDAQ: OPK) has transferred the rights to its product RAYALDEE® in Japan from Japan Tobacco (JT) to Vifor Fresenius Medical Care Renal Pharma (VFMCRP). The agreement follows JT's decision to terminate its exclusive rights based on a review of its pipeline. EirGen Pharma will now work with VFMCRP under an existing agreement for the product's commercialization in Japan and other markets. RAYALDEE® treats secondary hyperparathyroidism in chronic kidney disease patients and is approved in the U.S. and 11 European countries.
OPKO Health, Inc. (NASDAQ: OPK) has entered into exchange agreements with certain noteholders to convert $55.42 million of its 4.50% Convertible Senior Notes due 2025 into shares of common stock. The exchange will be based on a volume-weighted average price with a floor price of $3.50 per share, starting today. Additionally, OPKO will pay accrued interest to the noteholders in cash. This move is expected to reduce the outstanding borrowed shares related to a previous share lending agreement with Jefferies Capital Services.